Dr. Jonathan A. Rosenberg, M.D.
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Medical school
- University of Illinois College of Med (Chi/Peor/Rock/Chm-Urb) (2004)
- Years since graduation
- 22
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 572
Licensed in Illinois since 2006, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2004Medical school: University of Illinois College of Med (Chi/Peor/Rock/Chm-Urb)
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
IL license 036117327 (first issued 2006; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Northshore University Healthsystem - Evanston Hospital Evanston, IL
- Northwestern Lake Forest Hospital Lake Forest, IL
- Advocate Condell Medical Center Libertyville, IL
- Vista Medical Center East Waukegan, IL
Medical groups
- Illinois Gastroenterology Group LLC (115 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 572
- Services billed
- 7,685
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 207 | 159 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 108 | 108 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 101 | 98 |
| New patient office or other outpatient visit, 45-59 minutes | 95 | 95 |
| Established patient office or other outpatient visit, 20-29 minutes | 92 | 80 |
| Biopsy of large bowel using a flexible endoscope | 84 | 84 |
| Established patient office or other outpatient visit, 40-54 minutes | 79 | 79 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 28 | 27 |
| New patient office or other outpatient visit, 30-44 minutes | 24 | 24 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 21 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Omeprazole Other prescribers in Gurnee, IL | 446 |
| Gavilyte-G (peg3350/sod sulf,bicarb,cl/kcl) Other prescribers in Gurnee, IL | 171 |
| Pantoprazole Sodium Other prescribers in Gurnee, IL | 163 |
| Linzess (linaclotide) Other prescribers in Gurnee, IL | 135 |
| Peg-3350 And Electrolytes (peg3350/sod sulf,bicarb,cl/kcl) Other prescribers in Gurnee, IL | 84 |
| Sod Sulf-Potass Sulf-Mag Sulf (sodium, potassium,mag sulfates) Other prescribers in Gurnee, IL | 70 |
| Mesalamine Other prescribers in Gurnee, IL | 52 |
| Sucralfate Other prescribers in Gurnee, IL | 38 |
| Gavilyte-C (peg3350/sod sulf,bicarb,cl/kcl) Other prescribers in Gurnee, IL | 38 |
| Sutab (sod sulf/pot chloride/mag sulf) | 26 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 22 companies reported 315 payments worth $140,200 in total to this clinician.
| AbbVie Inc. | $36,584 |
|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $18,321 |
| Lilly USA, LLC | $17,283 |
| Janssen Biotech, Inc. | $12,728 |
| Phathom Pharmaceuticals, Inc. | $12,520 |
| Aimmune Therapeutics, Inc. | $11,715 |
| Genzyme Corporation | $11,138 |
| Regeneron Healthcare Solutions, Inc. | $10,593 |
| Compensation for services other than consulting (speaking, faculty) | $118,095 |
|---|---|
| Travel and Lodging | $8,039 |
| Consulting Fee | $7,983 |
| Food and Beverage | $6,084 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. Jan 28, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $7,293 |
| Genzyme Corporation Feb 27, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $7,293 |
| Takeda Pharmaceuticals U.S.A., Inc. Sep 17, 2025 | Compensation for services other than consulting (speaking, faculty) ENTYVIO · INTERNAL MEDICINE | $5,729 |
| Takeda Pharmaceuticals U.S.A., Inc. Oct 14, 2025 | Compensation for services other than consulting (speaking, faculty) ENTYVIO · INTERNAL MEDICINE | $5,729 |
| AbbVie Inc. Nov 17, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $5,600 |
| Takeda Pharmaceuticals U.S.A., Inc. Feb 25, 2025 | Compensation for services other than consulting (speaking, faculty) ENTYVIO · INTERNAL MEDICINE | $4,381 |
| Aimmune Therapeutics, Inc. May 12, 2025 | Compensation for services other than consulting (speaking, faculty) ZENPEP · ENDOCRINE PANCREATIC INSUFFICIENCY | $4,125 |
| AbbVie Inc. Nov 13, 2025 | Compensation for services other than consulting (speaking, faculty) SKYRIZI · IMMUNOLOGY | $4,000 |
| AbbVie Inc. Nov 19, 2025 | Compensation for services other than consulting (speaking, faculty) SKYRIZI · IMMUNOLOGY | $4,000 |
| AbbVie Inc. Jun 24, 2025 | Compensation for services other than consulting (speaking, faculty) LINZESS · GASTROENTEROLOGY | $4,000 |
All 72 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. Dec 18, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $1,600 |
| Madrigal Pharmaceuticals Dec 15, 2025 | Consulting Fee | $1,058 |
| AbbVie Inc. Nov 20, 2025 | Compensation for services other than consulting (speaking, faculty) VIBERZI · GASTROENTEROLOGY | $2,400 |
| AbbVie Inc. Nov 19, 2025 | Compensation for services other than consulting (speaking, faculty) SKYRIZI · IMMUNOLOGY | $4,000 |
| Genzyme Corporation Nov 19, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $3,003 |
| AbbVie Inc. Nov 19, 2025 | Travel and Lodging SKYRIZI · IMMUNOLOGY · travel to CHICAGO, IL · in-kind | $506 |
| AbbVie Inc. Nov 17, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $5,600 |
| AbbVie Inc. Nov 13, 2025 | Compensation for services other than consulting (speaking, faculty) SKYRIZI · IMMUNOLOGY | $4,000 |
| AbbVie Inc. Oct 29, 2025 | Travel and Lodging RINVOQ · IMMUNOLOGY · travel to BELOIT, WI · in-kind | $586 |
| Phathom Pharmaceuticals, Inc. Oct 29, 2025 | Travel and Lodging VOQUEZNA · Gastroenterology · travel to Schaumburg, IL | $47.24 |
| Madrigal Pharmaceuticals Oct 28, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $3,878 |
| Madrigal Pharmaceuticals Oct 28, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to VERNON HILLS, IL | $13.58 |
| Janssen Biotech, Inc. Oct 25, 2025 | Compensation for services other than consulting (speaking, faculty) STELARA; TREMFYA · Immunology | $1,400 |
| Takeda Pharmaceuticals U.S.A., Inc. Oct 24, 2025 | Travel and Lodging ENTYVIO · INTERNAL MEDICINE · travel to CHAMPAIGN, IL · in-kind | $246 |
| Takeda Pharmaceuticals U.S.A., Inc. Oct 24, 2025 | Travel and Lodging ENTYVIO · INTERNAL MEDICINE · travel to CHAMPAIGN, IL · in-kind | $6.00 |
| AbbVie Inc. Oct 22, 2025 | Travel and Lodging SKYRIZI · IMMUNOLOGY · travel to OAK BROOK, IL · in-kind | $437 |
| Takeda Pharmaceuticals U.S.A., Inc. Oct 14, 2025 | Compensation for services other than consulting (speaking, faculty) ENTYVIO · INTERNAL MEDICINE | $5,729 |
| Phathom Pharmaceuticals, Inc. Oct 8, 2025 | Compensation for services other than consulting (speaking, faculty) VOQUEZNA · Gastroenterology | $3,500 |
| Takeda Pharmaceuticals U.S.A., Inc. Sep 25, 2025 | Travel and Lodging ENTYVIO · INTERNAL MEDICINE · travel to CHAMPAIGN, IL · in-kind | $268 |
| Takeda Pharmaceuticals U.S.A., Inc. Sep 17, 2025 | Compensation for services other than consulting (speaking, faculty) ENTYVIO · INTERNAL MEDICINE | $5,729 |
| Lilly USA, LLC Sep 5, 2025 | Compensation for services other than consulting (speaking, faculty) OMVOH · Immunology | $1,250 |
| Takeda Pharmaceuticals U.S.A., Inc. Sep 3, 2025 | Travel and Lodging ENTYVIO · INTERNAL MEDICINE · travel to BELOIT, WI · in-kind | $681 |
| Pfizer Inc. Aug 8, 2025 | Compensation for services other than consulting (speaking, faculty) VELSIPITY · INFLAMMATION;PAIN | $375 |
| AbbVie Inc. Aug 4, 2025 | Consulting Fee | $400 |
| Janssen Biotech, Inc. Aug 2, 2025 | Compensation for services other than consulting (speaking, faculty) TREMFYA · Immunology | $3,150 |
| Madrigal Pharmaceuticals Jul 31, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $2,115 |
| AbbVie Inc. Jul 29, 2025 | Consulting Fee RINVOQ · IMMUNOLOGY | $400 |
| Janssen Biotech, Inc. Jul 26, 2025 | Travel and Lodging TREMFYA · Immunology · travel to CHICAGO, IL · in-kind | $507 |
| Janssen Biotech, Inc. Jul 19, 2025 | Compensation for services other than consulting (speaking, faculty) STELARA; TREMFYA · Immunology | $875 |
| AbbVie Inc. Jul 16, 2025 | Compensation for services other than consulting (speaking, faculty) SKYRIZI · IMMUNOLOGY | $4,000 |
| Aimmune Therapeutics, Inc. Jul 10, 2025 | Compensation for services other than consulting (speaking, faculty) ZENPEP · ENDOCRINE PANCREATIC INSUFFICIENCY | $3,000 |
| Aimmune Therapeutics, Inc. Jul 10, 2025 | Travel and Lodging ZENPEP · ENDOCRINE PANCREATIC INSUFFICIENCY · travel to Kenosha, WI · in-kind | $52.92 |
| AbbVie Inc. Jun 24, 2025 | Compensation for services other than consulting (speaking, faculty) LINZESS · GASTROENTEROLOGY | $4,000 |
| Lilly USA, LLC Jun 23, 2025 | Compensation for services other than consulting (speaking, faculty) OMVOH · Immunology | $2,500 |
| Lilly USA, LLC Jun 23, 2025 | Compensation for services other than consulting (speaking, faculty) OMVOH · Immunology | $1,575 |
| Lilly USA, LLC Jun 19, 2025 | Travel and Lodging travel to BROOKFIELD, WI · in-kind | $744 |
| Lilly USA, LLC Jun 13, 2025 | Compensation for services other than consulting (speaking, faculty) OMVOH · Immunology | $1,250 |
| Aimmune Therapeutics, Inc. Jun 9, 2025 | Travel and Lodging ZENPEP · ENDOCRINE PANCREATIC INSUFFICIENCY · travel to Creve Coeur, MO · in-kind | $193 |
| Aimmune Therapeutics, Inc. Jun 9, 2025 | Travel and Lodging ZENPEP · ENDOCRINE PANCREATIC INSUFFICIENCY · travel to Creve Coeur, MO · in-kind | $99.00 |
| Aimmune Therapeutics, Inc. Jun 9, 2025 | Travel and Lodging ZENPEP · ENDOCRINE PANCREATIC INSUFFICIENCY · travel to Kenosha, WI · in-kind | $52.78 |
| Aimmune Therapeutics, Inc. Jun 9, 2025 | Travel and Lodging ZENPEP · ENDOCRINE PANCREATIC INSUFFICIENCY · travel to Creve Coeur, MO · in-kind | $29.82 |
| Aimmune Therapeutics, Inc. May 28, 2025 | Compensation for services other than consulting (speaking, faculty) ZENPEP · ENDOCRINE PANCREATIC INSUFFICIENCY | $2,813 |
| AbbVie Inc. May 20, 2025 | Compensation for services other than consulting (speaking, faculty) VIBERZI · GASTROENTEROLOGY | $2,400 |
| Lilly USA, LLC May 19, 2025 | Consulting Fee OMVOH · Immunology | $3,125 |
| Lilly USA, LLC May 19, 2025 | Consulting Fee OMVOH · Immunology | $2,200 |
| Phathom Pharmaceuticals, Inc. May 14, 2025 | Travel and Lodging VOQUEZNA · Gastroenterology · travel to Lindenhurst, IL | $31.64 |
| Aimmune Therapeutics, Inc. May 12, 2025 | Compensation for services other than consulting (speaking, faculty) ZENPEP · ENDOCRINE PANCREATIC INSUFFICIENCY | $4,125 |
| Janssen Biotech, Inc. May 10, 2025 | Compensation for services other than consulting (speaking, faculty) TREMFYA · Immunology | $1,400 |
| Janssen Biotech, Inc. May 3, 2025 | Compensation for services other than consulting (speaking, faculty) TREMFYA · Immunology | $2,100 |
| Lilly USA, LLC May 2, 2025 | Travel and Lodging travel to SAN DIEGO, CA · in-kind | $487 |
| Lilly USA, LLC May 2, 2025 | Travel and Lodging travel to SAN DIEGO, CA · in-kind | $165 |
| AbbVie Inc. Apr 30, 2025 | Consulting Fee RINVOQ · IMMUNOLOGY | $800 |
| Aimmune Therapeutics, Inc. Apr 29, 2025 | Travel and Lodging ZENPEP · ENDOCRINE PANCREATIC INSUFFICIENCY · travel to Creve Coeur, MO · in-kind | $724 |
| Aimmune Therapeutics, Inc. Apr 29, 2025 | Travel and Lodging ZENPEP · ENDOCRINE PANCREATIC INSUFFICIENCY · travel to Creve Coeur, MO · in-kind | $177 |
| Phathom Pharmaceuticals, Inc. Apr 23, 2025 | Compensation for services other than consulting (speaking, faculty) VOQUEZNA · Gastroenterology | $2,800 |
| Phathom Pharmaceuticals, Inc. Apr 9, 2025 | Travel and Lodging VOQUEZNA · Gastroenterology · travel to Vernon Hills, IL | $13.44 |
| Lilly USA, LLC Mar 26, 2025 | Compensation for services other than consulting (speaking, faculty) OMVOH · Immunology | $1,250 |
| Regeneron Healthcare Solutions, Inc. Mar 21, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $2,431 |
| AbbVie Inc. Mar 20, 2025 | Compensation for services other than consulting (speaking, faculty) SKYRIZI · IMMUNOLOGY | $1,600 |
| Janssen Biotech, Inc. Mar 8, 2025 | Compensation for services other than consulting (speaking, faculty) TREMFYA · Immunology | $1,390 |
| Phathom Pharmaceuticals, Inc. Mar 5, 2025 | Compensation for services other than consulting (speaking, faculty) VOQUEZNA · Gastroenterology | $2,800 |
| Genzyme Corporation Feb 27, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $7,293 |
| Genzyme Corporation Feb 27, 2025 | Travel and Lodging DUPIXENT · Immunology · travel to Wauwatosa, WI · in-kind | $575 |
| Lilly USA, LLC Feb 26, 2025 | Compensation for services other than consulting (speaking, faculty) OMVOH · Immunology | $2,500 |
| Takeda Pharmaceuticals U.S.A., Inc. Feb 25, 2025 | Compensation for services other than consulting (speaking, faculty) ENTYVIO · INTERNAL MEDICINE | $4,381 |
| Takeda Pharmaceuticals U.S.A., Inc. Jan 29, 2025 | Travel and Lodging ENTYVIO · INTERNAL MEDICINE · travel to CHICAGO, IL · in-kind | $605 |
| Regeneron Healthcare Solutions, Inc. Jan 28, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $7,293 |
| Regeneron Healthcare Solutions, Inc. Jan 24, 2025 | Travel and Lodging DUPIXENT · IMMUNOLOGY AND INFLAMMATION · travel to BELOIT, WI · in-kind | $774 |
| Janssen Biotech, Inc. Jan 20, 2025 | Compensation for services other than consulting (speaking, faculty) TREMFYA · Immunology | $1,390 |
| Phathom Pharmaceuticals, Inc. Jan 15, 2025 | Travel and Lodging VOQUEZNA · Gastroenterology · travel to GURNEE, IL | $19.16 |
| AbbVie Inc. Jan 7, 2025 | Compensation for services other than consulting (speaking, faculty) VIBERZI · GASTROENTEROLOGY | $2,400 |
| Phathom Pharmaceuticals, Inc. Jan 3, 2025 | Compensation for services other than consulting (speaking, faculty) VOQUEZNA · Gastroenterology | $2,800 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 23 industry-funded studies in 2025, from 13 companies. The companies reported $708,726 in research payments for these studies, mostly to the institutions running them.
- A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)
Genzyme Corporation · Active, not recruiting · NCT06101095 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease
AbbVie Inc. - Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to se…
Boehringer Ingelheim International GmbH - A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection
Ferring Pharmaceuticals As - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.
AbbVie Inc. · Active, not recruiting · NCT06063967 - A Phase 1, open-label, single-sequence study to evaluate potential disease-mediated drug-drug interaction with selected cytochrome P450 substrates in adult subjects with active eosinophilic esophagitis receiving cenda…
Celgene Corporation - A Phase 3, Multi-Center, Multi-National, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Active Eosinophilic Esophagitis.
E.r. Squibb & Sons, L.l.c. - Roche Cancer Screening Collection Study
Genentech, Inc. - A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2)
Genentech, Inc. - An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice
E.r. Squibb & Sons, L.l.c. · Terminated · NCT05369832
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.